Disease · MONDO_0005072
Comparisons in its trials40
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 40
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Regimen A vs Regimen B: serious adverse events | 10 of 112 | 785 of 1,328 | 1,440 | NCT00026312 | Trial comparisons |
| Disease Evaluable by I-MIBG Scintigraphy (ABT-751) vs Measurable Disease by CT or MRI Scan (ABT-751): serious adverse events | 3 of 44 | 4 of 47 | 91 | NCT00436852 | Trial comparisons |
| Regimen A (Chemotherapy, Dinutuximab, Sargramostim) vs Regimen B (Eflornithine, Chemotherapy, Dinutuximab): deaths from any cause | 13 of 44 | 19 of 47 | 91 | NCT03794349 | Trial comparisons |
| Regimen A (Chemotherapy, Dinutuximab, Sargramostim) vs Regimen B (Eflornithine, Chemotherapy, Dinutuximab): serious adverse events | 3 of 44 | 20 of 47 | 91 | NCT03794349 | Trial comparisons |
| Arm I (Temozolomide, Irinotecan Hydrochloride, Temsirolimus) vs Arm II (Temozolomide, Irinotecan Hydrochloride, Dinutuximab): deaths from any cause | 12 of 18 | 15 of 51 | 69 | NCT01767194 | Trial comparisons |
| Arm I (Temozolomide, Irinotecan Hydrochloride, Temsirolimus) vs Arm II (Temozolomide, Irinotecan Hydrochloride, Dinutuximab): serious adverse events | 5 of 18 | 18 of 51 | 69 | NCT01767194 | Trial comparisons |
Disease Eval by Bone Marrow or MIBG (Irinotecan/Temozolomide) vs Disease Measurable by CT or MRI Scan (Irinotecan/Temozolomide): Overall Response - Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR) | 5 of 27 | 3 of 28 | 55 | NCT00311584 | Trial comparisons |
| Disease Eval by Bone Marrow or MIBG (Irinotecan/Temozolomide) vs Disease Measurable by CT or MRI Scan (Irinotecan/Temozolomide): serious adverse events | 0 of 27 | 1 of 28 | 55 | NCT00311584 | Trial comparisons |
| UTC ch14.18 vs NCI ch14.18: serious adverse events | 17 of 27 | 12 of 27 | 54 | NCT01592045 | Trial comparisons |
| Arm I (Chemotherapy, Immunoglobulin Therapy) vs Arm II (Chemotherapy, Observation): serious adverse events | 1 of 26 | 1 of 27 | 53 | NCT00033293 | Trial comparisons |
| Arm I (Chemotherapy, Immunoglobulin Therapy) vs Arm II (Chemotherapy, Observation): Number of Responders | 21 of 26 | 11 of 26 | 52 | NCT00033293 | Trial comparisons |
| Disease Measured by Standard Radiographic Criteria vs Disease Evaluable Only by I-MIBG or BM Histology: serious adverse events | 7 of 16 | 18 of 36 | 52 | NCT01334515 | Trial comparisons |
| Poor Risk Patients vs Good Risk Patients: Dose Limiting Veno-occlusive Disease (VOD) / Sinusoidal Obstruction Syndrome SOS | 6 of 42 | 0 of 8 | 50 | NCT00253435 | Trial comparisons |
| Poor Risk Patients vs Good Risk Patients: Engraftment DLT | 2 of 42 | 1 of 8 | 50 | NCT00253435 | Trial comparisons |
| Poor Risk Patients vs Good Risk Patients: serious adverse events | 12 of 42 | 3 of 8 | 50 | NCT00253435 | Trial comparisons |
| Poor Risk Patients vs Good Risk Patients: Response (Complete Response, Very Good Partial Response, and Partial Response) at 60-days Post Stem Cell Infusion | 4 of 41 | 3 of 8 | 49 | NCT00253435 | Trial comparisons |
| 13-CRA Oral Liquid vs 13-CRA Extracted Capsule: deaths from any cause | 0 of 20 | 0 of 20 | 40 | NCT03291080 | Trial comparisons |
| 13-CRA Oral Liquid vs 13-CRA Extracted Capsule: serious adverse events | 10 of 20 | 5 of 20 | 40 | NCT03291080 | Trial comparisons |
| Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: Toxicity | 6 of 6 | 24 of 26 | 32 | NCT00923351 | Trial comparisons |
| Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: deaths from any cause | 0 of 6 | 1 of 26 | 32 | NCT00923351 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005072/comparisons